Replimune (REPL) Interest Expenses (2017 - 2026)
Replimune (REPL) posted Interest Expenses of $3.6 million for Q1 2026, down 91.3% sequentially from $41.6 million in Q4 2025, and up 3221.55% YoY from $109015.3 in Q1 2025.
Replimune (REPL) Interest Expenses (2017 - 2026) Analysis & Trends
Replimune has reported Interest Expenses for 10 years, with the latest figure at $3.6 million in Q1 2026.
- Quarterly Interest Expenses rose 3221.55% year-over-year to $3.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.9 million (up 95.01% YoY) and the FY2026 annual result came in at $312.0 million, up 40.79% from the prior year.
- Interest Expenses fell to $3.6 million in Q1 2026 per REPL's latest filing, from $41.6 million in the prior quarter.
- Over five years, Interest Expenses peaked at $51.0 million in Q2 2022 and troughed at -$242000.0 in Q1 2022.
- A 5-year average of $33.2 million and a median of $44.4 million in 2024 frame the typical range for Interest Expenses.
- The sharpest annual moves came in 2022 and 2026: Interest Expenses tumbled 232.97% in 2022, then soared 3221.55% in 2026.
- Over 5 years, Interest Expenses stood at $49.7 million in 2022, then declined by 5.27% to $47.1 million in 2023, then slipped by 5.73% to $44.4 million in 2024, then dropped by 6.26% to $41.6 million in 2025, then plunged by 91.3% to $3.6 million in 2026.
- According to Business Quant data, Interest Expenses over the past three periods registered $3.6 million, $41.6 million, and $42.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Replimune | 1.24 Bn | 1.24 Bn | - | 2.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.62 Mn |
| Mar 31, 2026 | 3.62 Mn |
| Dec 31, 2025 | 41.61 Mn |
| Dec 31, 2025 | 41.61 Mn |
| Sep 30, 2025 | 42.32 Mn |
| Sep 30, 2025 | 42.32 Mn |
| Jun 30, 2025 | 43.02 Mn |
| Jun 30, 2025 | 43.02 Mn |
| Mar 31, 2025 | -116,000.00 |
| Mar 31, 2025 | -116,000.00 |
| Dec 31, 2024 | 44.39 Mn |
| Dec 31, 2024 | 44.39 Mn |
| Sep 30, 2024 | 45.08 Mn |
| Sep 30, 2024 | 45.08 Mn |
| Jun 30, 2024 | 45.75 Mn |
| Jun 30, 2024 | 45.75 Mn |
| Mar 31, 2024 | 2.46 Mn |
| Mar 31, 2024 | 2.46 Mn |
| Dec 31, 2023 | 47.09 Mn |
| Dec 31, 2023 | 47.09 Mn |